To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Vizz

Aceclidine
Antiglaucoma Agents
Ophthalmic Solution/Drops

Vizz is the first and only aceclidine-based eye drop approved for adults with presbyopia. Presbyopia is an age-related blurry near vision. By selectively contracting the iris sphincter muscle to create a pinhole effect and achieve a sub-2 mm pupil—without significant ciliary muscle stimulation—it extends depth of focus to provide fast, steroid-free relief of near-vision blur that lasts up to 10 hours. It offers a safe, once-daily, non-surgical alternative to traditional reading glasses and contact lenses.

Approval Date
31-Jul-25
NCE-1 Date
31-Jul-29
NCE Date
31-Jul-30
Commercial snapshot

Market performance & projections

Revenue ($M)
2
CAGR (%)
246.11%
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
22
2027
81
2028
174
2029
287
2030
375
2031
441
2032
499
Molecule profile

Details & specifications

Molecule
Aceclidine
Innovator
LENZ THERAPEUTICS INC
Dosage Form
Ophthalmic Solution/Drops
Strength
EQ 1.44% base
Therapeutic Category
Antiglaucoma Agents
Usage
To treat presbyopia
Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?